Merit Medical Systems, Inc.  

(Public, NASDAQ:MMSI)   Watch this stock  
Find more results for Nolan E. Karras
+0.20 (1.27%)
After Hours: 15.92 0.00 (0.00%)
Feb 8, 4:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.57 - 16.58
52 week 15.47 - 26.42
Open 15.68
Vol / Avg. 247,308.00/244,418.00
Mkt cap 682.42M
P/E 26.27
Div/yield     -
EPS 0.61
Shares 44.20M
Beta 1.01
Inst. own 91%
Feb 22, 2016
Q4 2015 Merit Medical Systems Inc Earnings Call - 5:00PM EST - Add to calendar
Feb 22, 2016
Q4 2015 Merit Medical Systems Inc Earnings Release - 4:00PM EST - Add to calendar
Dec 1, 2015
Merit Medical Systems Inc at Piper Jaffray Healthcare Conference
Nov 19, 2015
Merit Medical Systems Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 16, 2015
Merit Medical Systems Inc at Barclays MedTech/Tools SMID Cap Day
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 3.54% 4.51%
Operating margin 6.28% 7.88%
EBITD margin - 15.15%
Return on average assets 2.54% 3.11%
Return on average equity 4.24% 5.46%
Employees 3,105 -
CDP Score - -


1600 W Merit Pkwy
SOUTH JORDAN, UT 84095-2416
United States - Map
+1-801-2531600 (Phone)
+1-801-2531652 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merit Medical Systems, Inc. (Merit) is a designer, developer, manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures across the world. The Company operates in the diagnostic and interventional cardiology, interventional radiology, interventional gastroenterology, interventional pulmonology, thoracic surgery, interventional nephrology, vascular surgery, oncology, electrophysiology, cardiac rhythm management and pain management markets. It operates in segments: cardiovascular and endoscopy. Its cardiovascular segment comprises cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes the embolotherapeutic products. Its endoscopy segment comprises gastroenterology and pulmonology devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.

Officers and directors

Fred P. Lampropoulos Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bernard Birkett Chief Financial Officer
Bio & Compensation  - Reuters
Ronald A. Frost Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Kent W. Stanger Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
A. Scott Anderson Independent Director
Age: 68
Bio & Compensation  - Reuters
Richard W. Edelman Independent Director
Age: 74
Bio & Compensation  - Reuters
Nolan E. Karras Independent Director
Age: 70
Bio & Compensation  - Reuters
Franklin J. Miller Independent Director
Age: 74
Bio & Compensation  - Reuters